Evidence map›Paper›PMID 29463236›Full record

ArticleBMC cancer2018

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.

Xiao-Dong Jiao, Chunming Ding, Yuan-Sheng Zang, Guanzhen Yu

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Leptomeningeal carcinomatosis in gastric cancer: A Review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Review
  2. Article
  3. Article
  4. Leptomeningeal metastasis fromTranslational cancer research · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xiao-Dong JiaoDepartment of Medical Oncology, Changzheng Hospital, Shanghai, China.
Chunming DingSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Zhejiang, China.
Yuan-Sheng ZangDepartment of Medical Oncology, Changzheng Hospital, Shanghai, China. doctorzangys@163.com.
Guanzhen YuSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Zhejiang, China. qiaoshanqian@aliyun.com.
Shanghai Changzheng Hospital · CNWenzhou Medical University · CN

Funding

International Science and Technology Cooperation Program of China 2014DFA33010National Natural Science Foundation of China 81572856Shanghai Municipal Health and Family Planning Commission Foundation 201540174Shanghai Pujiang Program 13PJD002Young Start-up Foundation of Changzheng Hospital 2015CZQN07
6 · The paper itself

Abstract

backgroundGastric cancer patients with widespread metastasis, especially meningeal metastases, have an extremely prognosis and limited therapeutic choices. CASE PRESENTATION: We reported the case of a 39-year-old male patient with HER2-positive gastric cancer with bone and meningeal metastases. He presented with multiple bone metastases and received 3 cycles of docetaxel plus S1. However, he complained with headache and imaging examinations revealed leptomeningeal carcinomatosis. FISH revealed that tumor cells in the cerebrospinal fluid were HER-positive. Herceptin was added to the regimen, but the symptoms were not relieved, the patient suffered from dizziness and nausea. The chemotherapy regimen was switched d to lapatinib (orally at 1250 mg/day, every day), capecitabine (orally at 1000 mg/m2, bid for 2 weeks, followed by a 1-week rest interval, as 1 cycle) and Herceptin (390 mg/3 weeks). After 3 weeks of the new treatment, all the symptoms relieved. The clinical complete response was maintained for 3 months.

conclusionsLapatinib/Capecitabine combination therapy is an alternative treatment strategy for leptomeningeal carcinomatosis of HER2-positive gastric cancer in which trastuzumab and/or chemotherapy essentially has no effect.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBiomarkers, TumorCapecitabineDiagnostic ImagingErb-b2 Receptor Tyrosine KinasesHumansIn Situ Hybridization, FluorescenceLapatinibMaleMeningeal CarcinomatosisMultimodal ImagingNeoplasm MetastasisQuinazolinesStomach NeoplasmsBiomarkersBiomarkers, TumorCapecitabineErb-b2 Receptor Tyrosine KinasesLapatinibQuinazolinesTrastuzumabGastric cancerHER2LapatinibLeptomeningeal Carcinomatosis

Identifiers

PMID29463236
PMCPMC5819655
OpenAlexW2797584967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.